Neuroendocrine Carcinoma Treatment Market

Table of Content

1. Executive Summary

    1.1. Global Neuroendocrine Carcinoma Treatment Market Snapshot, 2024 and 2031

    1.2. Market Opportunity Assessment, 2024 - 2031, US$ Mn

    1.3. Key Market Trends

    1.4. Future Market Projections

    1.5. Premium Market Insights

    1.6. Industry Developments and Key Market Events 

    1.7. PMR Analysis and Recommendations

2. Market Overview

    2.1. Market Scope and Definition

    2.2. Market Dynamics

        2.2.1. Drivers

        2.2.2. Restraints

        2.2.3. Opportunity

        2.2.4. Challenges

        2.2.5. Key Trends

    2.3. Macro-Economic Factors

        2.3.1. Global GDP Growth Outlook

        2.3.2. Global Healthcare Spending Outlook

    2.4. COVID-19 Impact Analysis

    2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights 

    3.1. Product Adoption Analysis

    3.2. Epidemiology - Carcinoma

    3.3. Regulatory Landscape

    3.4. Value Chain Analysis

    3.5. Key Deals and Mergers

    3.6. PESTLE Analysis

    3.7. Porter's Five Force Analysis 

4. Global Neuroendocrine Carcinoma Treatment Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)

    4.1. Global Neuroendocrine Carcinoma Treatment Market Outlook: Indication

        4.1.1. Introduction / Key Findings

        4.1.2. Historical Market Size (US$ Mn) Analysis, By Indication, 2018 - 2022

        4.1.3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031

            4.1.3.1. Gastric Neuroendocrine Tumors

            4.1.3.2. Lung Neuroendocrine Tumors

            4.1.3.3. Pancreatic Neuroendocrine Tumors

            4.1.3.4. Appendicular Neuroendocrine Tumors

    4.2. Market Attractiveness Analysis: Indication

    4.3. Global Neuroendocrine Carcinoma Treatment Market Outlook: Treatment Type

        4.3.1. Introduction / Key Findings

        4.3.2. Historical Market Size (US$ Mn) Analysis, By Treatment Type, 2018 - 2022

        4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2023 - 2031

            4.3.3.1. Targeted Therapy

                4.3.3.1.1. Tyrosine Kinase Inhibitors

                4.3.3.1.2. mTOR Inhibitor

            4.3.3.2. Chemotherapy

                4.3.3.2.1. Antimetabolites

                4.3.3.2.2. Alkylating Agents

                4.3.3.2.3. Natural Products

            4.3.3.3. Surgery

                4.3.3.3.1. Curative Surgery

                4.3.3.3.2. Palliative Surgery

                4.3.3.3.3. Others

    4.4. Market Attractiveness Analysis: Treatment Type

    4.5. Global Neuroendocrine Carcinoma Treatment Market Outlook: End-user

        4.5.1. Introduction / Key Findings

        4.5.2. Historical Market Size (US$ Mn) Analysis, By End-user, 2018 - 2022

        4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2023 - 2031

            4.5.3.1. Hospitals

            4.5.3.2. Clinics

            4.5.3.3. Oncology Treatment Centers

            4.5.3.4. Ambulatory Surgical Centers

            4.5.3.5. Research Institutes

    4.6. Market Attractiveness Analysis: End-user

5. Global Neuroendocrine Carcinoma Treatment Market Outlook: Region

    5.1. Key Highlights

    5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2018 - 2022

    5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2023 - 2031

        5.3.1. North America

        5.3.2. Europe

        5.3.3. East Asia

        5.3.4. South Asia and Oceania

        5.3.5. Latin America

        5.3.6. Middle East & Africa

    5.4. Market Attractiveness Analysis: Region

6. North America Neuroendocrine Carcinoma Treatment Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031) 

    6.1. Key Highlights

    6.2. Pricing Analysis

    6.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022

        6.3.1. By Country

        6.3.2. By Indication

        6.3.3. By Treatment Type

    6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031

        6.4.1. U.S.

        6.4.2. Canada

    6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031

        6.5.1. Gastric Neuroendocrine Tumors

        6.5.2. Lung Neuroendocrine Tumors

        6.5.3. Pancreatic Neuroendocrine Tumors

        6.5.4. Appendicular Neuroendocrine Tumors

    6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2023 - 2031

        6.6.1. Targeted Therapy

            6.6.1.1. Tyrosine Kinase Inhibitors

            6.6.1.2. mTOR Inhibitor

        6.6.2. Chemotherapy

            6.6.2.1. Antimetabolites

            6.6.2.2. Alkylating Agents

            6.6.2.3. Natural Products

        6.6.3. Surgery

            6.6.3.1. Curative Surgery

            6.6.3.2. Palliative Surgery

        6.6.4. Others

    6.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2023 - 2031

        6.7.1. Hospitals

        6.7.2. Clinics

        6.7.3. Oncology Treatment Centers

        6.7.4. Ambulatory Surgical Centers

        6.7.5. Research Institutes

    6.8. Market Attractiveness Analysis

7. Europe Neuroendocrine Carcinoma Treatment Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)

    7.1. Key Highlights

    7.2. Pricing Analysis

    7.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022

        7.3.1. By Country

        7.3.2. By Indication

        7.3.3. By Treatment Type

        7.3.4. By End-user

    7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031

        7.4.1. Germany

        7.4.2. France

        7.4.3. U.K.

        7.4.4. Italy

        7.4.5. Spain

        7.4.6. Russia

        7.4.7. Türkiye

        7.4.8. Rest of Europe

    7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031

        7.5.1. Gastric Neuroendocrine Tumors

        7.5.2. Lung Neuroendocrine Tumors

        7.5.3. Pancreatic Neuroendocrine Tumors

        7.5.4. Appendicular Neuroendocrine Tumors

    7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2023 - 2031

        7.6.1. Targeted Therapy

            7.6.1.1. Tyrosine Kinase Inhibitors

            7.6.1.2. mTOR Inhibitor

        7.6.2. Chemotherapy

            7.6.2.1. Antimetabolites

            7.6.2.2. Alkylating Agents

            7.6.2.3. Natural Products

        7.6.3. Surgery

            7.6.3.1. Curative Surgery

            7.6.3.2. Palliative Surgery

        7.6.4. Others

    7.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2023 - 2031

        7.7.1. Hospitals

        7.7.2. Clinics

        7.7.3. Oncology Treatment Centers

        7.7.4. Ambulatory Surgical Centers

        7.7.5. Research Institutes

    7.8. Market Attractiveness Analysis

8. East Asia Neuroendocrine Carcinoma Treatment Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)

    8.1. Key Highlights

    8.2. Pricing Analysis

    8.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022

        8.3.1. By Country

        8.3.2. By Indication

        8.3.3. By Treatment Type

        8.3.4. By End-user 

    8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031

        8.4.1. China

        8.4.2. Japan

        8.4.3. South Korea

    8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031

        8.5.1. Gastric Neuroendocrine Tumors

        8.5.2. Lung Neuroendocrine Tumors

        8.5.3. Pancreatic Neuroendocrine Tumors

        8.5.4. Appendicular Neuroendocrine Tumors

    8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2023 - 2031

        8.6.1. Targeted Therapy

            8.6.1.1. Tyrosine Kinase Inhibitors

            8.6.1.2. mTOR Inhibitor

        8.6.2. Chemotherapy

            8.6.2.1. Antimetabolites

            8.6.2.2. Alkylating Agents

            8.6.2.3. Natural Products

        8.6.3. Surgery

            8.6.3.1. Curative Surgery

            8.6.3.2. Palliative Surgery

        8.6.4. Others

    8.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2023 - 2031

        8.7.1. Hospitals

        8.7.2. Clinics

        8.7.3. Oncology Treatment Centers

        8.7.4. Ambulatory Surgical Centers

        8.7.5. Research Institutes

    8.8. Market Attractiveness Analysis

9. South Asia & Oceania Neuroendocrine Carcinoma Treatment Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)

    9.1. Key Highlights

    9.2. Pricing Analysis

    9.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022

        9.3.1. By Country

        9.3.2. By Indication

        9.3.3. By Treatment Type

        9.3.4. By End-user 

    9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031

        9.4.1. India

        9.4.2. Southeast Asia

        9.4.3. ANZ

        9.4.4. Rest of South Asia & Oceania

    9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031

        9.5.1. Gastric Neuroendocrine Tumors

        9.5.2. Lung Neuroendocrine Tumors

        9.5.3. Pancreatic Neuroendocrine Tumors

        9.5.4. Appendicular Neuroendocrine Tumors

    9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2023 - 2031

        9.6.1. Targeted Therapy

            9.6.1.1. Tyrosine Kinase Inhibitors

            9.6.1.2. mTOR Inhibitor

        9.6.2. Chemotherapy

            9.6.2.1. Antimetabolites

            9.6.2.2. Alkylating Agents

            9.6.2.3. Natural Products

        9.6.3. Surgery

            9.6.3.1. Curative Surgery

            9.6.3.2. Palliative Surgery

        9.6.4. Others

    9.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2023 - 2031

        9.7.1. Hospitals

        9.7.2. Clinics

        9.7.3. Oncology Treatment Centers

        9.7.4. Ambulatory Surgical Centers

        9.7.5. Research Institutes

    9.8. Market Attractiveness Analysis

10. Latin America Neuroendocrine Carcinoma Treatment Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)

    10.1. Key Highlights

    10.2. Pricing Analysis

    10.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022

        10.3.1. By Country

        10.3.2. By Indication

        10.3.3. By Treatment Type

        10.3.4. By End-user 

    10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031

        10.4.1. Brazil

        10.4.2. Mexico

        10.4.3. Rest of Latin America

    10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031

        10.5.1. Gastric Neuroendocrine Tumors

        10.5.2. Lung Neuroendocrine Tumors

        10.5.3. Pancreatic Neuroendocrine Tumors

        10.5.4. Appendicular Neuroendocrine Tumors

    10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2023 - 2031

        10.6.1. Targeted Therapy

            10.6.1.1. Tyrosine Kinase Inhibitors

            10.6.1.2. mTOR Inhibitor

        10.6.2. Chemotherapy

            10.6.2.1. Antimetabolites

            10.6.2.2. Alkylating Agents

            10.6.2.3. Natural Products

        10.6.3. Surgery

            10.6.3.1. Curative Surgery

            10.6.3.2. Palliative Surgery

        10.6.4. Others

    10.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2023 - 2031

        10.7.1. Hospitals

        10.7.2. Clinics

        10.7.3. Oncology Treatment Centers

        10.7.4. Ambulatory Surgical Centers

        10.7.5. Research Institutes

    10.8. Market Attractiveness Analysis

11. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)

    11.1. Key Highlights

    11.2. Pricing Analysis

    11.3. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022

        11.3.1. By Country

        11.3.2. By Indication

        11.3.3. By Treatment Type

        11.3.4. By End-user 

    11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031

        11.4.1. GCC Countries

        11.4.2. Egypt

        11.4.3. South Africa

        11.4.4. Northern Africa

        11.4.5. Rest of Middle East & Africa

    11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031

        11.5.1. Gastric Neuroendocrine Tumors

        11.5.2. Lung Neuroendocrine Tumors

        11.5.3. Pancreatic Neuroendocrine Tumors

        11.5.4. Appendicular Neuroendocrine Tumors

    11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2023 - 2031

        11.6.1. Targeted Therapy

            11.6.1.1. Tyrosine Kinase Inhibitors

            11.6.1.2. mTOR Inhibitor

        11.6.2. Chemotherapy

            11.6.2.1. Antimetabolites

            11.6.2.2. Alkylating Agents

            11.6.2.3. Natural Products

        11.6.3. Surgery

            11.6.3.1. Curative Surgery

            11.6.3.2. Palliative Surgery

        11.6.4. Others

    11.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2023 - 2031

        11.7.1. Hospitals

        11.7.2. Clinics

        11.7.3. Oncology Treatment Centers

        11.7.4. Ambulatory Surgical Centers

        11.7.5. Research Institutes

    11.8. Market Attractiveness Analysis

12. Competition Landscape

    12.1. Market Share Analysis, 2023

    12.2. Market Structure

        12.2.1. Competition Intensity Mapping By Market 

        12.2.2. Competition Dashboard

    12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)

        12.3.1. Pfizer Inc.

            12.3.1.1. Overview

            12.3.1.2. Segments and Products

            12.3.1.3. Key Financials

            12.3.1.4. Market Developments

            12.3.1.5. Market Strategy

        12.3.2. Novartis AG

            12.3.2.1. Overview

            12.3.2.2. Segments and Products

            12.3.2.3. Key Financials

            12.3.2.4. Market Developments

            12.3.2.5. Market Strategy

        12.3.3. Chiasma Inc.

            12.3.3.1. Overview

            12.3.3.2. Segments and Products

            12.3.3.3. Key Financials

            12.3.3.4. Market Developments

            12.3.3.5. Market Strategy

        12.3.4. Hutchison China MediTech Ltd

            12.3.4.1. Overview

            12.3.4.2. Segments and Products

            12.3.4.3. Key Financials

            12.3.4.4. Market Developments

            12.3.4.5. Market Strategy

        12.3.5. Abbvie Inc.

            12.3.5.1. Overview

            12.3.5.2. Segments and Products

            12.3.5.3. Key Financials

            12.3.5.4. Market Developments

            12.3.5.5. Market Strategy

        12.3.6. valeant Pharmaceuticals International Inc.

            12.3.6.1. Overview

            12.3.6.2. Segments and Products

            12.3.6.3. Key Financials

            12.3.6.4. Market Developments

            12.3.6.5. Market Strategy

        12.3.7. Jubilant Life Sciences Ltd.

            12.3.7.1. Overview

            12.3.7.2. Segments and Products

            12.3.7.3. Key Financials

            12.3.7.4. Market Developments

            12.3.7.5. Market Strategy

        12.3.8. Teva Pharamaceuticals Industries Ltd

            12.3.8.1. Overview

            12.3.8.2. Segments and Products

            12.3.8.3. Key Financials

            12.3.8.4. Market Developments

            12.3.8.5. Market Strategy

        12.3.9. F. Hoffman-La Roche Ltd

            12.3.9.1. Overview

            12.3.9.2. Segments and Products

            12.3.9.3. Key Financials

            12.3.9.4. Market Developments

            12.3.9.5. Market Strategy

        12.3.10. Advanced Accelerator Applications

            12.3.10.1. Overview

            12.3.10.2. Segments and Products

            12.3.10.3. Key Financials

            12.3.10.4. Market Developments

            12.3.10.5. Market Strategy

        12.3.11. Mateon Therapeutics, Inc.

            12.3.11.1. Overview

            12.3.11.2. Segments and Products

            12.3.11.3. Key Financials

            12.3.11.4. Market Developments

            12.3.11.5. Market Strategy

13. Appendix

    13.1. Research Methodology

    13.2. Research Assumptions

    13.3. Acronyms and Abbreviations

List Of Table

- List Of Chart -